Therapeutic Advances and New Directions for Triple-Negative Breast Cancer

Eleni Andreopoulou, Catherine M. Kelly, Hayley M. McDaid

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is a molecularly diverse grouping with poor prognosis for which chemotherapy remains the foundation of treatment. The molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to treatment. Estimates of up to 20% of patients diagnosed have germline mutations in DNA-damage repair-pathway genes, namely BRCA1 and 2, and this can be used to select patients likely to respond to platinums and/or inhibitors of poly(ADP-ribose) polymerase (PARP). Similar strategies can be utilized in other subtypes of TNBC that have 'BRCA-like' tumor biology due to the presence of mutations in alternate DNA-damage repair genes. The diverse biological behavior of TNBC and its variable response to chemotherapy were largely decoded following genotyping studies that enabled the identification of distinct molecular subtypes, such that the biological and genetic heterogeneity of the disease could be understood. This subsequently enabled the identification of therapeutic 'vulnerabilities' for each subtype that encompass biological processes including proliferation, DNA repair, apoptosis, angiogenesis, immune modulation, and invasion and metastasis. To expedite the development of therapies for high-risk, early-stage breast cancer, we have adopted novel trial designs and re-defined endpoints as surrogates of clinical outcomes. The purpose of this review is to highlight the current standard and experimental treatment options for TNBC.

Original languageEnglish (US)
Pages (from-to)21-28
Number of pages8
JournalBreast Care
Volume12
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Triple Negative Breast Neoplasms
DNA Repair
DNA Damage
BRCA1 Gene
Biological Phenomena
Therapeutics
Drug Therapy
Inborn Genetic Diseases
Genetic Heterogeneity
Germ-Line Mutation
Biomarkers
Direction compound
Apoptosis
Breast Neoplasms
Neoplasm Metastasis
Mutation
Genes
Neoplasms

Keywords

  • BRCA
  • Cytotoxic chemotherapy
  • Genomics
  • Immunotherapy
  • Molecular subtypes
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Therapeutic Advances and New Directions for Triple-Negative Breast Cancer. / Andreopoulou, Eleni; Kelly, Catherine M.; McDaid, Hayley M.

In: Breast Care, Vol. 12, No. 1, 01.03.2017, p. 21-28.

Research output: Contribution to journalReview article

Andreopoulou, Eleni ; Kelly, Catherine M. ; McDaid, Hayley M. / Therapeutic Advances and New Directions for Triple-Negative Breast Cancer. In: Breast Care. 2017 ; Vol. 12, No. 1. pp. 21-28.
@article{cc63e65aac584a5d9cbdc303d56df640,
title = "Therapeutic Advances and New Directions for Triple-Negative Breast Cancer",
abstract = "Triple-negative breast cancer (TNBC) is a molecularly diverse grouping with poor prognosis for which chemotherapy remains the foundation of treatment. The molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to treatment. Estimates of up to 20{\%} of patients diagnosed have germline mutations in DNA-damage repair-pathway genes, namely BRCA1 and 2, and this can be used to select patients likely to respond to platinums and/or inhibitors of poly(ADP-ribose) polymerase (PARP). Similar strategies can be utilized in other subtypes of TNBC that have 'BRCA-like' tumor biology due to the presence of mutations in alternate DNA-damage repair genes. The diverse biological behavior of TNBC and its variable response to chemotherapy were largely decoded following genotyping studies that enabled the identification of distinct molecular subtypes, such that the biological and genetic heterogeneity of the disease could be understood. This subsequently enabled the identification of therapeutic 'vulnerabilities' for each subtype that encompass biological processes including proliferation, DNA repair, apoptosis, angiogenesis, immune modulation, and invasion and metastasis. To expedite the development of therapies for high-risk, early-stage breast cancer, we have adopted novel trial designs and re-defined endpoints as surrogates of clinical outcomes. The purpose of this review is to highlight the current standard and experimental treatment options for TNBC.",
keywords = "BRCA, Cytotoxic chemotherapy, Genomics, Immunotherapy, Molecular subtypes, Triple-negative breast cancer",
author = "Eleni Andreopoulou and Kelly, {Catherine M.} and McDaid, {Hayley M.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1159/000455821",
language = "English (US)",
volume = "12",
pages = "21--28",
journal = "Breast Care",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Therapeutic Advances and New Directions for Triple-Negative Breast Cancer

AU - Andreopoulou, Eleni

AU - Kelly, Catherine M.

AU - McDaid, Hayley M.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Triple-negative breast cancer (TNBC) is a molecularly diverse grouping with poor prognosis for which chemotherapy remains the foundation of treatment. The molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to treatment. Estimates of up to 20% of patients diagnosed have germline mutations in DNA-damage repair-pathway genes, namely BRCA1 and 2, and this can be used to select patients likely to respond to platinums and/or inhibitors of poly(ADP-ribose) polymerase (PARP). Similar strategies can be utilized in other subtypes of TNBC that have 'BRCA-like' tumor biology due to the presence of mutations in alternate DNA-damage repair genes. The diverse biological behavior of TNBC and its variable response to chemotherapy were largely decoded following genotyping studies that enabled the identification of distinct molecular subtypes, such that the biological and genetic heterogeneity of the disease could be understood. This subsequently enabled the identification of therapeutic 'vulnerabilities' for each subtype that encompass biological processes including proliferation, DNA repair, apoptosis, angiogenesis, immune modulation, and invasion and metastasis. To expedite the development of therapies for high-risk, early-stage breast cancer, we have adopted novel trial designs and re-defined endpoints as surrogates of clinical outcomes. The purpose of this review is to highlight the current standard and experimental treatment options for TNBC.

AB - Triple-negative breast cancer (TNBC) is a molecularly diverse grouping with poor prognosis for which chemotherapy remains the foundation of treatment. The molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to treatment. Estimates of up to 20% of patients diagnosed have germline mutations in DNA-damage repair-pathway genes, namely BRCA1 and 2, and this can be used to select patients likely to respond to platinums and/or inhibitors of poly(ADP-ribose) polymerase (PARP). Similar strategies can be utilized in other subtypes of TNBC that have 'BRCA-like' tumor biology due to the presence of mutations in alternate DNA-damage repair genes. The diverse biological behavior of TNBC and its variable response to chemotherapy were largely decoded following genotyping studies that enabled the identification of distinct molecular subtypes, such that the biological and genetic heterogeneity of the disease could be understood. This subsequently enabled the identification of therapeutic 'vulnerabilities' for each subtype that encompass biological processes including proliferation, DNA repair, apoptosis, angiogenesis, immune modulation, and invasion and metastasis. To expedite the development of therapies for high-risk, early-stage breast cancer, we have adopted novel trial designs and re-defined endpoints as surrogates of clinical outcomes. The purpose of this review is to highlight the current standard and experimental treatment options for TNBC.

KW - BRCA

KW - Cytotoxic chemotherapy

KW - Genomics

KW - Immunotherapy

KW - Molecular subtypes

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85011890565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011890565&partnerID=8YFLogxK

U2 - 10.1159/000455821

DO - 10.1159/000455821

M3 - Review article

AN - SCOPUS:85011890565

VL - 12

SP - 21

EP - 28

JO - Breast Care

JF - Breast Care

SN - 1661-3791

IS - 1

ER -